-
[Haematologica] Improved clinical outcomes of 7+3 induction regimens in AML over 40 years
Time of Update: 2022-08-15
. Early mortality, complete remission (CR) rates, and overall survival (OS) in acute myeloid leukemia (AML) patients treated with cytarabine in combination with anthracyclines (7+ 3) have been reported since the 1980s The extent to which OS increases with prolonged duration of first complete remission (CR1) and salvage therapy (including allogeneic hematopoietic cell transplantation) after first relapse has not been assessed; The relative contribution levels may provide some insight into the interpretation of past and current research .
-
Efficacy and safety of CD-19 CAR-T cells in the treatment of B-cell acute lymphoblastic leukemia with CNSL
Time of Update: 2022-08-15
In recent years, some studies have reported that patients with refractory secondary CNS diffuse large B-cell lymphoma (DLBCL) received CD19 CAR-T cell therapy and achieved CR with controllable and reversible neurotoxicity, confirming the entry of CAR-T cells into Efficient transport in the central nervous system .
-
Comments from Professor Zhang Qingyuan of Case Sharing: Selinesol treatment broke the dilemma of relapse and refractory, and R/R DLBCL patients achieved complete remission!
Time of Update: 2022-08-15
Clinical diagnosis: first-line treatment of diffuse large B-cell lymphoma R-CHOP regimen on December 3, 2018, a total of 2 courses, radiotherapy for abdominal enlarged lymph nodes 5400cGy/27F; R-CHOP regimen on March 8, 2019, a total of 2 courses Course of treatment; PET-CT showed disease progression (PD) in December 2019 .
-
New progress in the treatment of relapsed and refractory DLBCL
Time of Update: 2022-08-15
Through intensive reading of influential research literature in the field of lymphoma, discussion of hot topics in lymphoma diagnosis and treatment, and joint exploration and summary Optimized diagnosis and treatment strategies for lymphoma to improve the survival rate of Chinese lymphoma patients .
-
A rare case of M3 found in an unhealed over-the-wall fracture
Time of Update: 2022-08-12
, PML-RARa fusion gene detection (qualitative), RARa gene rearrangement detection (FISH) were negative The morphology of the bone marrow cells of this patient is consistent with M3, and the flow cytometry results are consistent with the immunophenotype of acute promyelocytic leukemia (APL).
-
AJH: CAR-T cell therapy targeting B-cell maturation antigen is effective in relapsed/refractory multiple myeloma, including cases with poor performance status
Time of Update: 2022-08-12
. In an open-label, single-arm, phase I/II clinical trial, investigators evaluated anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) therapy in 49 patients with relapsed/refractory Efficacy in multiple sclerosis myeloma (RRMM) patients, including 20 Eastern Cooperative Oncology Group (ECOG) grade 3-4 patients .
-
haematol: Distinctive ethnic characteristics of DDX41 mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia
Time of Update: 2022-08-12
DDX41 mutations are associated with hematological malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), but in patients with idiopathic cytopenia of undetermined significance (ICUS) It's not clear .
-
The sly "M protein"
Time of Update: 2022-08-12
The phenomenon of turbidity occurs, so what is the reason for this?Figure 4Figure 4The real reason is that when the sample is diluted with pure water, the ionic strength in the sample is reduced, which leads to cross-linking and aggregation of high immunoglobulins easily resulting in turbidity.
-
Ann Hematol: Potential risk factors for the development of immune thrombocytopenia to systemic lupus erythematosus: a case-control study in Chinese children
Time of Update: 2022-08-12
ANA positive may affect the development of SLE in children with ITP to a certain extentTherefore, studies recommend close follow-up for at least 3 years in pediatric ITP patients and up to 10 years in children with multiple risk factors to monitor the risk of developing SLE .
-
The diagnosis and differential diagnosis of aplastic anemia can be easily mastered in five minutes!
Time of Update: 2022-08-12
Bleeding:， 。， 。3-14，30 。、 。，7，、 。2-3 。3-14，30 。、 。，7，、 。2-3 。， 。6、 。， 。6、 。Diagnosis and classification of aplastic anemiaDiagnosis and classification of aplastic anemia1、、、1、、、1、、、， 。、，， 。， 。、，， 。，， 。， 。， 。，， 。， 。， 。 。 。2、2、2、 。 。（），，、，、， 。，MDS 。（），，、，、， 。，MDS 。2cm， 。、，、 。， 。 。2cm， 。、，、 。， 。 。3、3、3、：：：(1)，60， 。(、B19)、、、 。4.
-
Bone Marrow Transplant: Comparison of Fludarabine-Melphalan and Fludarabine-Triendosulfan as Conditioning Before Allogeneic Hematopoietic Cell Transplantation
Time of Update: 2022-08-12
In this study, a research team compared outcomes after two commonly used single alkylating agent-based conditioning regimens in the intermediate TCI score category, fludarabine/melphalan 140 mg/m 2 (FluMel) and Fludarabine/triendosulfan 42 g/m 2 (FluTreo) for acute myeloid leukemia (AML) patients in complete remission (CR) .
-
BJH: Daratumumab, lenalidomide, and dexamethasone in newly diagnosed patients with systemic light chain amyloidosis associated with multiple myeloma
Time of Update: 2022-08-12
In this retrospective cohort study, we analyzed 6-month hematologic and organ responses to daratumumab, lenalidomide, and dexamethasone (DRd), a newly diagnosed transplant-ineligible MM patient standard of care in 3 patients with MM with systemic AL amyloidosis at diagnosis .
-
The patient had 24 blood routine tests, but the latter two had abnormally high platelets
Time of Update: 2022-08-12
Almost the same platelet histogram, why are the last two false elevations so severe?The results of the last two platelet tests were significantly higher, and there was no significant difference in the platelet histograms of the previous blood routine tests of the patient.
-
Analysis of a rare clinical case of jelly-like serum
Time of Update: 2022-08-12
forewordforewordWe all know that blood is an important component of human life . Blood consists of cellular components (formed components) and acellular components (non-formed components) . Formed com
-
ICER evaluates Roctavian and EtranaDez gene therapy for hemophilia A and B
Time of Update: 2022-08-12
19 in the run-in period, meeting the primary noninferiority endpoint as well as secondary endpoints The results showed that the annualized bleeding rate (ABR) assessed 18 months after infusion decreased to 1.
-
The same critical value of white blood cells, the same increase in the proportion of lymphocytes, seems to be the same, but it is not
Time of Update: 2022-08-12
Could it be an uncommon lymphocytic leukemia reaction?At the same time, if a lymphoma patient has abnormally elevated lymphocytes, will the lymphoma invade the peripheral blood?
Could it be an uncommon lymphocytic leukemia reaction?At the same time, if a lymphoma patient has abnormally elevated lymphocytes, will the lymphoma invade the peripheral blood?
-
In many cases, the interference of chylous blood on blood routine is very likely to be ignored by us
Time of Update: 2022-08-10
Quickly check the blood routine results, see Figure 1April 12, 2022, night shift, when I was holding a specimen to review the biochemical results, I saw a sample with severe lipid turbidity.
-
coagulation factor activity PK lupus anticoagulant
Time of Update: 2022-08-10
What kind of adventures will happen if the coagulation factor activity measurement meets the lupus anticoagulant positive?case aftercase by case by caseIn April 2022, in the daily work, the results of a coagulation factor activity measurement caught the author's attention, as shown in Figure 1, the patient's endogenous coagulation factor (FVIII, FIX, FXI, FXIII) activity was significantly reduced .
-
Chemotherapy drug-allergic ALL patients new hope Eryaspas can be used for second-line treatment of acute lymphoblastic leukemia patients allergic to asparaginase
Time of Update: 2022-06-18
In the NOPHO ALL2008 regimen, 5 doses of PEG-asparaginase (1000 IU/m²/dose, intramuscularly) were administered to non-high-risk patients at 2-week intervals during the consolidation phase, starting on day 30 of treatment, followed by delayed intensive chemotherapy.
-
Impact of high-risk cytogenetic signatures on clinical outcomes in children and young adult patients receiving CD19-targeted CAR-T therapy
Time of Update: 2022-06-18
A separate analysis of specific cytogenetic abnormalities in high-risk patients showed no significant difference in RFS rates between KMT2A-rearranged (P=0.
